BEIJING, March 01, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the
InnoCare’s next-generation TRKi Zurletrectinib Receives Priority Review for the Treatment of Pediatric Patients with Solid Tumors in China
